Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Alchemab Therapeutics has raised $32.0M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Alchemab Therapeutics's investors include RA Capital Management, Eli Lilly, Lightstone Ventures, Dementia Discovery Fund, SV Health Investors.
Alchemab Therapeutics is headquartered in London, United Kingdom.
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Alchemab Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alchemab Therapeutics — Funding & Investors." VCBacked, September 9, 2025, https://www.vcbacked.co/company/alchemab-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Alchemab Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/alchemab-therapeutics
{{cite web |title=Alchemab Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alchemab-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated